Quick Answer
Celldex Therapeutics, Inc. reported R&D Expense of $245.07 million for fiscal year 2025.
Celldex Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $245.07M | +49.8% |
| 2024 | $163.55M | +38.6% |
| 2023 | $118.01M | +43.5% |
| 2022 | $82.26M | +54.3% |
| 2021 | $53.31M | +25.3% |
| 2020 | $42.53M | -0.3% |
| 2019 | $42.67M | -35.8% |
| 2018 | $66.45M | -30.9% |
| 2017 | $96.17M | -6.4% |
| 2016 | $102.73M | +2.6% |
| 2015 | $100.17M | -4.0% |
| 2014 | $104.38M | +54.9% |
| 2013 | $67.40M | +42.2% |
| 2012 | $47.40M | +46.1% |
| 2011 | $32.44M | +17.3% |
| 2010 | $27.65M | +5.7% |
| 2009 | $26.17M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $62.93M | +39.0% | +16.1% |
| June 30, 2025 | $54.20M | +36.6% | +3.0% |
| March 31, 2025 | $52.61M | +66.2% | +16.2% |
| September 30, 2024 | $45.26M | +31.1% | +14.0% |
| June 30, 2024 | $39.69M | +51.2% | +25.3% |
| March 31, 2024 | $31.66M | +18.1% | -8.3% |
| September 30, 2023 | $34.53M | +60.1% | +31.6% |
| June 30, 2023 | $26.25M | +26.6% | -2.0% |
- Celldex Therapeutics, Inc. showed an increase of +49.8% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, Celldex Therapeutics, Inc.’s r&d expense has grown by 836.5% (from $26.17 million to $245.07 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: